l.solberg
TL2 Moderator · Medellín
Contributes reviews on supplier material. Based in Medellín.
Joined 6 April 2025 · last posted 4d
80Posts here
4Topics
1Solutions
904Likes received
716Likes given
22Badges
193Days visited
3.5kPosts read
Recent activity
Full stream-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #93 · Practice › Dosing & titration · 24 Jul 2026 · 26 likes Worth separating two things that post #89 runs together. Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure,…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #34 · Access › Insurance & coverage · 16 Jul 2026 · 22 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Common supplements people ask about, assessed one at a time Replied, post #54 · Practice › Interactions · 16 Jul 2026 · 4 likes SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to interactions. There is no pharmacokinetic interaction of concern.
-
What I would want from a home test that does not exist yet Replied, post #37 · Analytics › Home & field testing · 14 Jul 2026 · 0 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #36 · Evidence › Journal club · 8 Jul 2026 · 0 likes SURMOUNT-1 (N Engl J Med 2022): Tirzepatide obesity trial. The largest mean weight reduction for a pharmacological intervention at publication. Read the categorical…
-
Journal club: what we got wrong in an earlier session Replied, post #61 · Evidence › Journal club · 7 Jul 2026 · 11 likes SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two…
-
Personal or family history of medullary thyroid carcinoma — what changed since Replied, post #93 · Safety › Contraindications · 30 Jun 2026 · 25 likes Severe renal impairment (eGFR
-
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Replied, post #67 · Compounds › Semaglutide · 17 Jun 2026 · 0 likes post #66 is right about the mechanism and I think understates the practical bit. The SELECT trial changed the positioning because it was the first cardiovascular…
-
Revisiting: Can a home kit substitute for a laboratory report? A careful no Replied, post #35 · Analytics › Home & field testing · 15 Jun 2026 · 10 likes What you can use home tests for: confirmation that a solution contains peptide (as opposed to being saline alone), rough screening for very different compounds…
-
A reconstituted vial's beyond-use date and the reasoning behind common figures Replied, post #111 · Practice › Storage & stability · 9 Jun 2026 · 24 likes This follows post #108 rather than contradicting it. Dating prepared solutions: write the date reconstitution on the vial in permanent marker. If you later need to know…
-
Pooling trials with different estimands Replied, post #9 · Evidence › Meta-analyses · 6 Jun 2026 · 8 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just… Replied, post #114 · Compounds › Tirzepatide · 1 Jun 2026 · 13 likes Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a…